Table 2 Select immunotherapy agents and ongoing immunotherapy clinical trials in RCC
Ongoing clinical trials for check point inhibitors | |||
 Trial | National clinical trial identifier | Status | Disease setting |
 Neoadjuvant durvalumab +/− tremelimumab | NCT02762006 | Recruiting | Neoadjuvant |
 Neoadjuvant pembro | NCT02212730 | Recruiting | Neoadjuvant |
 Neoadjuvant nivolumab | NCT02595918 | Recruiting | Neoadjuvant |
 Neoadjuvant nivolumab | NCT02575222 | Recruiting | Neoadjuvant |
 Nivo vs. nivo + bev vs. nivo + ipi | NCT02210117 | Recruiting | Neoadjuvant |
 Nivo pre and post-surgery | NCT02446860 | Recruiting | Neoadjuvant/adjuvant |
 Phase I pembro + pazopanib | NCT02014636 | Recruiting | Refractory |
 Phase III nivo vs. everolimus | NCT01668784 | Stopped early and reported in 2015 | Refractory |
 Nivo + sunitinib or pazopanib or ipi | NCT01472081 | Active, not recruiting | Refractory |
 Pembro + RT | NCT02318771 | Recruiting | Refractory |
 Phase Ib/II pembro + len in solid tumors | NCT02501096 | Recruiting solid tumors including RCC | Refractory |
Ongoing IL-2 based clinical trials | |||
 Trial | National clinical trial identifier | Status | |
 HD IL-2 + HQ | NCT01550367 | Recruiting | |
 IL-2 +/− SBRT | NCT02306954 | Recruiting | |
 IL-2 +/− RT | NCT01896271 | Recruiting | |
 PROCLAIM | NCT01415167 | Registry of HD IL-2 patients | |
 IL2 + entinostat | NCT01038778 | Ongoing, presented 2016 | |